BridgeBio reported positive Phase 3 results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), with 76% of treated patients meeting combined serum and urine calcium targets at 24 weeks versus 4% on conventional therapy. The drug also corrected parathyroid hormone levels in the majority of patients and was generally well tolerated. The success follows a separate late‑stage win from BridgeBio earlier in the week and strengthens the company’s pivot toward rare endocrine and genetic disorders. Management said it plans regulatory filings next year based on the ADH1 dataset. Positive Phase 3 outcomes for high‑need rare conditions can accelerate approval timelines and create attractive commercial opportunities despite small patient populations; BridgeBio said it will continue to support access and follow‑up care for treated patients while advancing regulatory submissions.